Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Current & emerging therapies for classic and variant HCL

Kerry Rogers • 12 Dec 2022
ASH 2022
Hairy Cell Leukemia Leukemia Antibodies BTK inhibitors Cladribine Moxetumomab pasudotox Pentostatin Rituximab Vemurafenib

Kerry Rogers, MD, The Ohio State University, Columbus, OH, gives an overview of advances in the treatment of classic and variant hairy cell leukemia (HCL). Dr Rogers explains that whilst purine nucleoside analogs such as cladribine and pentostatin with or without rituximab are the current standard of care (SOC) in HCL, there is a growing role for the use of other drugs such as vemurafenib and moxetumomab pasudotox in patients who do not benefit from purine analogs. In addition, Dr Rogers highlights the potential of BTK inhibitors in patients with variant HCL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Innate Pharma: Consultancy; Pharmacyclics: Consultancy; Beigene: Consultancy; AstraZeneca: Consultancy, Other: Travel Funding; Novartis: Research Funding; Janssen: Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding.

More from Kerry Rogers

2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
4:07
The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers • 8 Dec 2023
5:34
Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment
Kerry Rogers • 8 Dec 2023
1:18
Comorbidity and geriatric assessment tools in routine practice for CLL patients
Kerry Rogers • 7 Oct 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals